Noul Co Ltd.
KKRX:3769301,285.00
KRW
+32.00
(+2.55%)
ISIN
KR7376930004
Return %
Stock
S&P 500
1Y
-89.37
14.20
3Y
-92.81
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chan-Yang Lim
- Full Time Employees
- 130
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Yongin-si South Korea
- IPO Date
- Mar 3, 2022
- Website
- noul.com
- Similar Companies
- Business
- Noul Co., Ltd. is a South Korea-based medical artificial intelligence and in vitro diagnostics company that specializes in the development and commercialization of integrated, decentralized diagnostic platforms for blood analysis and cancer screening. Founded in 2015 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company operates within the biotechnology, digital healthcare, and medical device sectors, supplying clinical laboratories, hospitals, outpatient medical centers, decentralized healthcare facilities, and global health organizations across the Asia-Pacific, European, Latin American, Middle Eastern, and African markets. The company's proprietary technology is built upon the miLab (Micro-Intelligent Laboratory) ecosystem, an automated, cartridge-based benchtop diagnostic platform that integrates Next-Generation Staining and Immunostaining (NGSI) solid-state hydrogel stamping technology with embedded artificial intelligence optical analysis, eliminating the need for liquid reagents, manual washing steps, or traditional laboratory infrastructure. The company manufactures, markets, and distributes specialized hardware, single-use consumable test cartridges, and diagnostic software suites, including: the miLab Platform, an automated optical imaging and sample processing diagnostic device; the miLab MAL Cartridge, an in vitro diagnostic solution for automated malaria parasite detection, species identification, and parasitemia level quantification; the miLab BCM Cartridge, an automated peripheral blood smear analysis system providing white blood cell differential counts, red blood cell morphological analysis, and platelet estimation; the miLab CER Cartridge, an automated cervical cytology diagnostic solution for liquid-based cervical cancer screening aligned with the Bethesda reporting system; and proprietary diagnostic consumables, digital pathology software modules, and data management tools for decentralized hematology and cytology workflows. In recent developments, Noul Co., Ltd. has accelerated its international commercial expansion and advanced its clinical pipeline through strategic regulatory achievements, global distribution agreements, and public health alliances. The company has secured CE-IVD and CE-IVDR regulatory certifications across the European Union for its miLab platform and diagnostic cartridge portfolio, enabling market penetration into key European regions including Germany, Italy, Spain, and Poland through dedicated distributor networks. Noul has also deepened its participation in international public health initiatives through grant awards and joint validation studies supported by the RIGHT Foundation to deploy automated malaria diagnostic systems in high-burden, resource-limited regions. Furthermore, the company has expanded its oncology pipeline toward automated breast cancer tissue analysis, established regional commercial support operations in Europe, and executed multiple regional supply contracts across Latin America and the Middle East to broaden the global deployment of its AI-driven decentralized diagnostic solutions.